Importing pharmaceuticals from Israel into the US in 2026 means navigating multiple tariff layers. The current total effective rate runs approximately 10% on most pharmaceuticals imports under HTS chapters 30. The pre-SCOTUS IEEPA reciprocal rate on Israel was 17% — meaning importers who paid duties between April 2025 and February 2026 are owed an IEEPA refund of roughly 7% of declared value, plus ~5% statutory interest.
The current rate stack on pharmaceuticals from Israel breaks down as: the 10% Section 122 reciprocal tariff (effective February 24, 2026, set to expire July 24, 2026 unless extended), plus the MFN duty rate that depends on the specific HTS code, plus any product-specific surcharges.
For most importers, the 10% total represents a meaningful change from the pre-SCOTUS regime, when the IEEPA reciprocal layer pushed Israel pharmaceuticals imports to 17% effective. SCOTUS struck down the IEEPA reciprocal layer on February 20, 2026 in Learning Resources v. Trump, opening a refund pool of approximately $166 billion for affected importers.
If you imported pharmaceuticals from Israel between April 2025 and February 2026, the IEEPA refund window is still open through Phase 1 of CBP's CAPE portal — for entries that are unliquidated or within 80 days of liquidation. Phase 2 will cover older entries, reconciliation, and drawback claims when it launches later in 2026.
Bottom line for pharmaceuticals importers from Israel: confirm your HTS classification, account for the Section 122 layer (and Section 232/301 if applicable), and — if you paid IEEPA duties in 2025 — check your refund eligibility before the Phase 1 windows close on a rolling basis through Q3 2026.
Calculate Your Pharmaceuticals Duty from Israel
Frequently Asked Questions
What is the total tariff rate on pharmaceuticals from Israel in 2026?
The total effective US tariff on pharmaceuticals from Israel is approximately 10%, composed of the 10% Section 122 reciprocal tariff plus the MFN base rate plus any product-specific surcharges.
Can I get a refund on pharmaceuticals imported from Israel in 2025?
Yes. The pre-SCOTUS IEEPA reciprocal rate on Israel was 17% vs the current 10% Section 122 rate. Importers who paid the IEEPA layer between April 2025 and February 2026 are owed roughly 7% of declared value back, plus statutory interest at ~5%. Refunds flow through CBP's CAPE portal during Phase 1 for unliquidated entries and Phase 2 for older entries.
Does Section 232 apply to pharmaceuticals from Israel?
Section 232 applies to specific product categories (steel, aluminum, autos, copper, semiconductors, lumber) regardless of country. For pharmaceuticals specifically, Section 232 generally does not apply unless the goods fall under one of those covered categories.
